Table II.
Correlation between IMP3 expression and clinicopathological parameters.
| IMP3 expression, n (%) | |||
|---|---|---|---|
|
|
|||
| Parameters | Positive | Negative | P-value |
| Age, years | |||
| <65 | 64 (33.5) | 47 (24.6) | 0.6179 |
| ≥65 | 49 (25.7) | 31 (16.2) | |
| Gender | |||
| Male | 97 (50.8) | 70 (36.6) | 0.4191 |
| Female | 16 (8.4) | 8 (4.2) | |
| Histologya | |||
| Poor/moderate | 89 (46.6) | 55 (28.8) | 0.1955 |
| Well | 24 (12.6) | 23 (12.0) | |
| Neoadjuvant chemotherapy | |||
| Yes | 48 (25.1) | 38 (19.9) | 0.4654 |
| No | 65 (34.0) | 40 (20.9) | |
| Depth of tumor invasionb | |||
| pT1–2 | 35 (18.3) | 46 (24.1) | 0.0010 |
| pT3–4 | 78 (40.8) | 32 (16.8) | |
| Lymph node metastasisb | |||
| pN0 | 33 (17.3) | 35 (18.3) | 0.0267 |
| pN1–3 | 80 (41.9) | 43 (22.5) | |
| pStageb | |||
| I, II | 67 (35.1) | 46 (24.1) | 0.0003 |
| III, IV | 46 (24.1) | 32 (16.8) | |
a
Well-, moderately- and poorly-differentiated squamous cell carcinoma.
b
According to the Union for International Cancer Control, 7th edition (21).
pN; pathological N stage; pT, pathological T stage; pStage, pathological stage; IMP3, insulin-like growth factor-II mRNA-binding protein-3.